<DOC>
	<DOCNO>NCT01787110</DOCNO>
	<brief_summary>The use supplemental oxygen set suspect acute myocardial infarction ( AMI ) manifest international treatment guideline establish prehospital hospital clinical routine throughout world . However , date conclusive evidence adequately design powered trial support practice . Existing data conflict fail clarify role supplemental oxygen AMI . The DETO2X-AMI trial design shed light important issue .</brief_summary>
	<brief_title>An Efficacy Outcome Study Supplemental Oxygen Treatment Patients With Suspected Myocardial Infarction</brief_title>
	<detailed_description>AIM : The aim DETO2X-AMI trial evaluate role supplemental oxygen delivery set acute coronary syndrome myocardial infarction include ST-segment elevation myocardial infarction ( STEMI ) , non ST-segment elevation myocardial infarction ( NSTEMI ) unstable angina ( UA ) . DESIGN : DETO2X-AMI multicentre , interventional , control , randomize registry base clinical trial ( RRCT ) recruiting 6600 patient cardiac care facility report SWEDEHEART registry throughout whole Sweden . The SWEDEHEART ( Swedish Web-system Enhancement Development Evidence-based care Heart disease Evaluated According Recommended Therapies ) registry nationwide use platform allow broad population all-comers access broad registry network include : - RIKS-HIA ( nationwide registry ischemia case treat cardiac intensive care unit register ) , - SCAAR ( Swedish Coronary Angiography Angioplasty Registry nationwide coronary angiography percutaneous coronary intervention ( PCI ) procedure register ) ) - SEPHIA ( nationwide registry post AMI follow-up patient 75 year age ) . All follow-up carry SWEDEHEART national registry national cause death register ( dödsorsaksregister ) national patient register ( slutenvårdsregister ) . A similar set-up successfully use TASTE ( Thrombus Aspiration ST-Elevation myocardial infarction Scandinavia ) trial . MATERIAL METHODS : Patients normal oxygen saturation ( ≥90 % pulse oximeter ) present ambulance service emergency department ( ED ) classical symptom suggestive acute coronary syndrome ( ACS ) significant ECG change elevate cardiac biomarkers ( ED ) evaluate inclusion . If eligible , oral inform consent obtain EMD ED personnel prior inclusion . Randomization carry cardiac intensive care unit use web-based tool part registration directly national SWEDEHEART registry . Patients randomize either supplemental oxygen deliver oxymask® ( 6 L/min ) 12 hour ( min 6 hour ) supplemental O₂ . All patient receive standard care accord international ACS guideline include acute coronary intervention . EFFICACY OUTCOMES : Primary efficacy outcome All-cause mortality one year patient suspect AMI ( ITT ) . Secondary efficacy outcome In ITT population AMI cohort : - MACE 1 : composite all-cause mortality rehospitalization heart failure* - MACE 2 : composite all-cause mortality rehospitalization heart failure readmission myocardial infarction - rehospitalization heart failure - rehospitalization AMI - rehospitalization shock ( Kilip ≥3 ) * - cardiovascular death * - health economy In STEMI cohort : MACE composite all-cause death , rehospitalization MI , cardiogenic shock , stent thrombosis* plus . *These outcome specify trial start , treatment comparison available . Primary secondary outcome assess 30 day one year follow . Supplementary per-protocol analysis perform . Subgroup analyse consist predefined subgroup include gender , age , AMI/Non-AMI , Type-I AMI ( STEMI/NSTEMI ) , smoker , Hb , oxygen saturation level , patient chronic obstructive pulmonary disease , chronic kidney disease diabetes mellitus . Two main sub study perform : DETO2X-Biomarkers , multicenter sub study DETO2X-AMI trial assess oxygen treatment enhances oxidative stress , systemic inflammation , marker apoptosis MMPs ACS patient , thereby potentially increase myocardial damage cell death , potentially prognosis ( see separate trial protocol clinicaltrials.gov NCT02290080 detail ) . DETO2X-OXYPAIN 2 , multicenter sub study DETO2X-AMI trial center catheter laboratory evaluate possible analgesic effect oxygen use visual-analog scale ( VAS ) . Follow-up carry accord clinical post AMI routine include standardized registration SWEDEHEART registry . Mortality data obtain national cause death register link SWEDEHEART . CONCLUSION : There conclusive evidence adequately design powered trial support routine administration supplemental oxygen set suspect AMI . The DETO2X-AMI trial design shed light important issue give guidance future recommendation .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<criteria>symptom ( chest pain , dyspnea ) indicate acute myocardial ischemia within last 6 hour ECG change ( STsegment elevation ≥ 2 mm V1V4 , ≥ 1 mm lead , STsegment depression &gt; 1 mm lead , negative Twave lead V2V6 , pathological Qwave least 2 adjacent lead ) , leave bundle branch block and/or elevate level cardiac troponin level ED indicate acute myocardial ischemia oxygen saturation ≥90 % ( pulse oximeter ) age ≥30 unwillingness participate inability comprehend give information continuous oxygen delivery home prior inclusion cardiac arrest prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Non ST-segment Myocardial Infarction</keyword>
	<keyword>ST-segment Myocardial Infarction</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Oxygen</keyword>
	<keyword>Unstable angina</keyword>
	<keyword>Randomised trial</keyword>
	<keyword>CMR</keyword>
	<keyword>Mortality</keyword>
	<keyword>RCRT</keyword>
	<keyword>RRCT</keyword>
</DOC>